Avrobio is stopping enrollment in a clinical trial for its Fabry disease program after new results showed variability in how the gene therapy was taken up by patients. No safety problems were reported, but the biotech said it now plans to focus its other gene therapy candidates for rare metabolic disorders.
Toronto, Ontario (Newsfile Corp. - August 13, 2021) - Satellos Bioscience Inc. (formerly iCo Therapeutics Inc.) (TSXV: MSCL) ("Satellos" or the "Company") is pleased to announce the completion, following
Gene therapy for Fabry: early stages, promising results biopharmadive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharmadive.com Daily Mail and Mail on Sunday newspapers.